Candel Therapeutics Inc (CADL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $486.37M
Last updated: Nov 17, 2026 at 11:04 AM ET
Candel Therapeutics Inc (CADL) Competitors
The companies most similar to Candel Therapeutics are CytomX Therapeutics (CTMX), Century Therapeutics (IPSC) and Indaptus Therapeutics (INDP). By market cap, Candel Therapeutics ranks 5th of the 13 companies on this page; Kura Oncology (KURA) is the largest at $713.90M.
Peer Comparison
CADL's ROIC of -43.5% is below the peer median of -32.8%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Candel Therapeutics (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Century Therapeutics Inc (IPSC) | $299.63M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Peer median | $433.55M | N/A | 16.3x | 0.0% | -32.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Candel Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Century Therapeutics Inc (IPSC) | Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy... | IPSC competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health... | KYTX competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
Frequently Asked Questions About CADL
Who are Candel Therapeutics' main competitors?
The companies most similar to Candel Therapeutics include CytomX Therapeutics (CTMX), Century Therapeutics (IPSC), Indaptus Therapeutics (INDP), Cullinan Oncology LLC (CGEM) and Avalo Therapeutics (AVTX), listed from the closest match.
Who is Candel Therapeutics' biggest competitor?
Kura Oncology (KURA) is the largest of the similar companies at $713.90M; CytomX Therapeutics (CTMX) is the closest match by business profile, size, sector and industry.
How does CADL stock compare with its competitors?
CADL's net margin is 0.0% against a peer median of 0.0%.
Which of Candel Therapeutics' competitors pays a higher dividend?
Candel Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Candel Therapeutics bigger than its competitors?
No. Candel Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Kura Oncology (KURA) at $713.90M.
CADL pages: Overview, Earnings, Forecast, Financials, Competitors